The global cancer biomarkers market size was US$ 12.7 billion in 2022 and is expected to hit over US$ 36.2 billion by 2031, registering a CAGR of 13% during the forecast period from from 2023 to 2031.
Cancer biomarkers are traceable chemicals or compounds that indicate the presence of malignant cells in the body. A significant strategy for achieving quick findings for treatment is the prevention of cancer by identifying and examining several cancer biomarkers using various diagnostic procedures. Biomarkers come in a variety of forms, including proteins, peptides, antibodies, and nucleic acids.
Market Driving Factors
Increased cancer incidence worldwide and more acceptance of cancer therapies in developing nations are some factors influencing market expansion. For instance, according to data from the American Cancer Society's Cancer Facts & Figures 2022 report, there were an estimated 1.9 million new cancer cases diagnosed in the United States (US) in 2022. Additionally, according to the GLOBOCAN 2020 report, by 2030, there will be 24,044,406 new instances of cancer, indicating an increasing global incidence of the disease.
The market's revenue growth is increasing by technological advancements in biomarker discovery and development. The development of high-throughput technologies like genomics, proteomics, and metabolomics has aided in the identification of novel biomarkers for cancer detection and diagnosis. The expanding use of artificial intelligence and machine learning in the discovery and development of biomarkers is likely to continue driving market revenue growth in the next years.
However, the high cost of diagnostic tests based on biomarkers may slow down the overall market expansion. Cancer biomarker-based assays are less frequently employed in situations with low resources since they are frequently more expensive than traditional diagnostic methods. For market participants, the regulatory framework for biomarker-based diagnostics is currently under development.
Market Segmentation Analysis
By Type Analysis
In 2022, the breast cancer segment held the highest revenue share in the cancer biomarkers market. The World Health Organization (WHO) estimates that 2.3 million women worldwide had breast cancer in 2020, with 685,000 deaths. By the end of 2020, 7.8 million women had been diagnosed with breast cancer in the previous five years, making it the most frequent cancer worldwide. Consequently, the rising incidence of breast cancer drives the segment growth.
By Application Analysis
In 2022, the diagnostic segment generated the highest revenue share. The segment is expected to grow due to factors including the expanding development of cancer biomarkers based on oncology tests with high efficiency and efficacy and expanding government efforts.
Regional Analysis
In 2022, North America dominated the cancer biomarkers market. In North America, the U.S. dominated the market for cancer biomarkers. There are several market participants in the cancer biomarkers industry functioning in the North American region. The American government is making significant investments in R&D projects to create new products. The market in North America is also expanding owing to the use of cutting-edge technologies.
On the other hand, Asia-Pacific is likely to experience the highest growth during the projection period. The rising incidence of cancer is fueling the market for cancer biomarkers in the Asia-Pacific region. Additionally, the government continuously funds research and development initiatives for the creation of new goods. As a result, growing interest in cancer biomarkers is fueling the market's expansion in the Asia-Pacific region.
Leading Players
Segmentation Outline
The cancer biomarkers market segmentation focuses on Type, Biomolecule, Application, Profiling Technology, End-User, and Region.
By Type
By Biomolecule
By Application
By Profiling Technology
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL CANCER BIOMARKERS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: CANCER BIOMARKERS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL CANCER BIOMARKERS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL CANCER BIOMARKERS MARKET, BY TYPE
5.1 OVERVIEW
5.2 BREAST CANCER
5.3 PROSTATE CANCER
5.4 COLORECTAL CANCER
5.5 CERVICAL CANCER
5.6 LIVER CANCER
5.7 LUNG CANCER
5.8 OTHERS
6 GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE
6.1 OVERVIEW
6.2 GENETIC BIOMARKERS
6.3 EPIGENETIC BIOMARKERS
6.4 METABOLIC BIOMARKERS
6.5 PROTEOMIC BIOMARKERS
6.6 OTHERS
7 GLOBAL CANCER BIOMARKERS MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 DRUG DISCOVERY AND DEVELOPMENT
7.3 DIAGNOSTICS
7.4 PERSONALIZED MEDICINE
7.5 OTHERS
8 GLOBAL CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY
8.1 OVERVIEW
8.2 OMIC TECHNOLOGIES
8.3 IMAGING TECHNOLOGIES
8.4 IMMUNOASSAYS
8.5 CYTOGENETICS-BASED TESTS
9 GLOBAL CANCER BIOMARKERS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 ACADEMIC AND CANCER RESEARCH INSTITUTES
9.4 AMBULATORY SURGICAL CENTRES
9.5 DIAGNOSTIC LABORATORIES
10 GLOBAL CANCER BIOMARKERS MARKET, BY GEOGRAPHY
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA MARKET SNAPSHOT
10.2.2 U.S.
10.2.3 CANADA
10.2.4 MEXICO
10.3 EUROPE
10.3.1 EUROPE MARKET SNAPSHOT
10.3.2 WESTERN EUROPE
10.3.2.1 THE UK
10.3.2.2 GERMANY
10.3.2.3 FRANCE
10.3.2.4 ITALY
10.3.2.5 SPAIN
10.3.2.6 REST OF WESTERN EUROPE
10.3.3 EASTERN EUROPE
10.3.3.1 POLAND
10.3.3.2 RUSSIA
10.3.3.3 REST OF EASTERN EUROPE
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC MARKET SNAPSHOT
10.4.2 CHINA
10.4.3 JAPAN
10.4.4 INDIA
10.4.5 AUSTRALIA & NEW ZEALAND
10.4.6 ASEAN
10.4.7 REST OF ASIA PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
10.5.2 UAE
10.5.3 SAUDI ARABIA
10.5.4 SOUTH AFRICA
10.5.5 REST OF MEA
10.6 SOUTH AMERICA
10.6.1 SOUTH AMERICA MARKET SNAPSHOT
10.6.2 BRAZIL
10.6.3 ARGENTINA
10.6.4 REST OF SOUTH AMERICA
11 GLOBAL CANCER BIOMARKERS MARKET COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPANY MARKET RANKING
11.3 KEY DEVELOPMENT STRATEGIES
11.4 COMPETITIVE DASHBOARD
11.5 PRODUCT MAPPING
11.6 TOP PLAYER POSITIONING, 2022
11.7 COMPETITIVE HEATMAP
11.8 TOP WINNING STRATEGIES
12 COMPANY PROFILES
12.1 F. HOFFMANN-LA ROCHE LTD.
12.1.1 OVERVIEW
12.1.2 FINANCIAL PERFORMANCE
12.1.3 PRODUCT OUTLOOK
12.1.4 KEY DEVELOPMENTS
12.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.2 THERMO FISHER SCIENTIFIC INC.
12.2.1 OVERVIEW
12.2.2 FINANCIAL PERFORMANCE
12.2.3 PRODUCT OUTLOOK
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.3 QIAGEN N.V.
12.3.1 OVERVIEW
12.3.2 FINANCIAL PERFORMANCE
12.3.3 PRODUCT OUTLOOK
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.4 ILLUMINA INC.
12.4.1 OVERVIEW
12.4.2 FINANCIAL PERFORMANCE
12.4.3 PRODUCT OUTLOOK
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.5 BIO-RAD LABORATORIES INC.
12.5.1 OVERVIEW
12.5.2 FINANCIAL PERFORMANCE
12.5.3 PRODUCT OUTLOOK
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.6 ABBOTT LABORATORIES
12.6.1 OVERVIEW
12.6.2 FINANCIAL PERFORMANCE
12.6.3 PRODUCT OUTLOOK
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.7 ABBOTT LABORATORIES
12.7.1 OVERVIEW
12.7.2 FINANCIAL PERFORMANCE
12.7.3 PRODUCT OUTLOOK
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.8. MESO SCALE DIAGNOSTICS LLC
12.8.1 OVERVIEW
12.8.2 FINANCIAL PERFORMANCE
12.8.3 PRODUCT OUTLOOK
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.9 SEEGENE TECHNOLOGIES INC.
12.9.1 OVERVIEW
12.9.2 FINANCIAL PERFORMANCE
12.9.3 PRODUCT OUTLOOK
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.10 SIEMENS HEALTHINEERS
12.10.1 OVERVIEW
12.10.2 FINANCIAL PERFORMANCE
12.10.3 PRODUCT OUTLOOK
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved